These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 30234721)

  • 1. Innate immunity and Toll-like receptor signaling in the pathogenesis of scleroderma: advances and opportunities for therapy.
    Brown M; O'Reilly S
    Curr Opin Rheumatol; 2018 Nov; 30(6):600-605. PubMed ID: 30234721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging roles of innate immune signaling and toll-like receptors in fibrosis and systemic sclerosis.
    Bhattacharyya S; Varga J
    Curr Rheumatol Rep; 2015 Jan; 17(1):474. PubMed ID: 25604573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous ligands of TLR4 promote unresolving tissue fibrosis: Implications for systemic sclerosis and its targeted therapy.
    Bhattacharyya S; Varga J
    Immunol Lett; 2018 Mar; 195():9-17. PubMed ID: 28964818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of innate immune system in systemic sclerosis.
    Fullard N; O'Reilly S
    Semin Immunopathol; 2015 Sep; 37(5):511-7. PubMed ID: 26159672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracellular Matrix-Derived Damage-Associated Molecular Patterns (DAMP): Implications in Systemic Sclerosis and Fibrosis.
    Bale S; Verma P; Varga J; Bhattacharyya S
    J Invest Dermatol; 2023 Oct; 143(10):1877-1885. PubMed ID: 37452808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-Like Receptor-4 Signaling Drives Persistent Fibroblast Activation and Prevents Fibrosis Resolution in Scleroderma.
    Bhattacharyya S; Midwood KS; Yin H; Varga J
    Adv Wound Care (New Rochelle); 2017 Oct; 6(10):356-369. PubMed ID: 29062592
    [No Abstract]   [Full Text] [Related]  

  • 7. Innate immunity in systemic sclerosis pathogenesis.
    O'Reilly S
    Clin Sci (Lond); 2014 Mar; 126(5):329-37. PubMed ID: 24219159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innate Immunity in Systemic Sclerosis.
    Dowson C; Simpson N; Duffy L; O'Reilly S
    Curr Rheumatol Rep; 2017 Jan; 19(1):2. PubMed ID: 28116578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toll-like receptors and their role in renal pathologies.
    Eleftheriadis T; Pissas G; Liakopoulos V; Stefanidis I; Lawson BR
    Inflamm Allergy Drug Targets; 2012 Dec; 11(6):464-77. PubMed ID: 22931389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toll Like Receptors in systemic sclerosis: An emerging target.
    O'Reilly S
    Immunol Lett; 2018 Mar; 195():2-8. PubMed ID: 28888416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toll-like receptors in mediating pathogenesis in systemic sclerosis.
    Frasca L; Lande R
    Clin Exp Immunol; 2020 Jul; 201(1):14-24. PubMed ID: 32048277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms and pathways of innate immune activation and regulation in health and cancer.
    Cui J; Chen Y; Wang HY; Wang RF
    Hum Vaccin Immunother; 2014; 10(11):3270-85. PubMed ID: 25625930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toll-like receptors and Type I interferons.
    Uematsu S; Akira S
    J Biol Chem; 2007 May; 282(21):15319-23. PubMed ID: 17395581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes.
    Farina A; Peruzzi G; Lacconi V; Lenna S; Quarta S; Rosato E; Vestri AR; York M; Dreyfus DH; Faggioni A; Morrone S; Trojanowska M; Farina GA
    Arthritis Res Ther; 2017 Feb; 19(1):39. PubMed ID: 28245863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAGE and TLRs: relatives, friends or neighbours?
    Ibrahim ZA; Armour CL; Phipps S; Sukkar MB
    Mol Immunol; 2013 Dec; 56(4):739-44. PubMed ID: 23954397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts.
    Raschi E; Chighizola CB; Cesana L; Privitera D; Ingegnoli F; Mastaglio C; Meroni PL; Borghi MO
    Arthritis Res Ther; 2018 Aug; 20(1):187. PubMed ID: 30157947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toll-like receptor triggering in systemic sclerosis: time to target.
    O'Reilly S
    Rheumatology (Oxford); 2023 Feb; 62(SI):SI12-SI19. PubMed ID: 35863054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogen recognition and Toll-like receptor targeted therapeutics in innate immune cells.
    Tartey S; Takeuchi O
    Int Rev Immunol; 2017 Mar; 36(2):57-73. PubMed ID: 28060562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of toll-like receptors in systemic sclerosis.
    Ciechomska M; Cant R; Finnigan J; van Laar JM; O'Reilly S
    Expert Rev Mol Med; 2013 Aug; 15():e9. PubMed ID: 23985302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll-like receptors and kidney diseases.
    Eleftheriadis T; Lawson BR
    Inflamm Allergy Drug Targets; 2009 Jul; 8(3):191-201. PubMed ID: 19601879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.